Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Swiss drugmaker Novartis buys US-based gene therapy company for $8.7 billion
April 9, 2018 Off

Swiss drugmaker Novartis buys US-based gene therapy company for $8.7 billion

By Dino Mustafić

Novartis’s acquisition of the US-based Nasdaq-listed clinical stage gene therapy company AveXis for $218 per share, for total of 8.7…

Encapsulated cell therapies for the potential treatment of type 1 diabetes from Lilly and Sigilon
April 6, 2018 Off

Encapsulated cell therapies for the potential treatment of type 1 diabetes from Lilly and Sigilon

By Dino Mustafić

Eli Lilly and Sigilon Therapeutics have announced a global collaboration to develop encapsulated cell therapies for the potential treatment of…

Nordic Nanovector’s CEO steps down
April 5, 2018 Off

Nordic Nanovector’s CEO steps down

By Dino Mustafić

Nordic Nanovector’s Chief Executive Officer Luigi Costa will step down, and the company will search for a new CEO immediately,…

Phase 3 study in second-line liver cancer patients met overall survival endpoint
April 4, 2018 Off

Phase 3 study in second-line liver cancer patients met overall survival endpoint

By Dino Mustafić

Eli Lilly has announced top-line results from its Phase 3 REACH-2 study of its second-line treatment for liver cancer CYRAMZA,…

Edinburgh-based pharmaceutical company Neurocentrx aims global market with new board members
April 3, 2018 Off

Edinburgh-based pharmaceutical company Neurocentrx aims global market with new board members

By Dino Mustafić

Neurocentrx, an Edinburgh-based pharmaceutical company, has appointed Nigel Brooksby as Non-Executive Chairman and Dr. Tim Corn as Non-Executive Director as…

Shire reaches regulatory milestones for investigational hereditary angioedema (HAE) treatment Lanadelumab
March 29, 2018 Off

Shire reaches regulatory milestones for investigational hereditary angioedema (HAE) treatment Lanadelumab

By Dino Mustafić

European Medicines Agency (EMA) has validated Shire’s marketing authorization application (MAA) for its lanadelumab, which was also accepted by Health…

EMA to review Sanofi’s potential treatment for type 1 diabetes
March 29, 2018 Off

EMA to review Sanofi’s potential treatment for type 1 diabetes

By Dino Mustafić

The European Medicines Agency (EMA) has accepted for review Sanofi’s regulatory submission for oral treatment sotagliflozin, developed in partnership with…

EMA accepts BioMarin’s Pegvaliase MAA for treatment of Phenylketonuria (PKU)
March 29, 2018 Off

EMA accepts BioMarin’s Pegvaliase MAA for treatment of Phenylketonuria (PKU)

By Dino Mustafić

European Medicines Agency (EMA) has accepted BioMarin’s submission of a Marketing Authorization Application (MAA) for pegvaliase for the treatment of…

Actinium to work with Astellas Pharma on its AWE Platform Technology
March 28, 2018 Off

Actinium to work with Astellas Pharma on its AWE Platform Technology

By Dino Mustafić

Actinium Pharmaceuticals and Astellas Pharma will work together to develop Actinium-225 Radio-Conjugates (ARCs) using Actinium Warhead Enabling (AWE) Platform Technology,…

First approved biosimilar from Biocon and Mylan’s joint portfolio in Europe
March 28, 2018 Off

First approved biosimilar from Biocon and Mylan’s joint portfolio in Europe

By Dino Mustafić

The European Commission has approved Mylan/Biocon’s co-developed biosimilar insulin glargine Semglee marketing authorization for people with diabetes after it got…

Posts pagination

Previous 1 … 3,393 3,394 3,395 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine